Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

INVO Bioscience to Report Q4 & Fiscal Year 2020 Financial Results on Tuesday, March 30 – Conference Call To Follow

By John F. Heerdink, Jr.

INVO Bioscience, Inc. (NASDAQ: INVO) is a medical device company focused on creating simplified, lower-cost treatments for patients diagnosed with infertility. Their solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Their lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care. For more information, please visit

INVO announced today that it will report financial results for its fourth quarter and fiscal year 2020, ended December 31, 2020, after the market close on Tuesday, March 30, 2021.

The Company has scheduled a conference call that same day, Tuesday, March 30, 2021, at 4:30 pm ET, to review the results.

Fourth Quarter and Fiscal Year 2020 Conference Call Details:

Date and Time: Tuesday, March 30, 2021 at 4:30 pm ET

Call-in Information: Interested parties can access the conference call by dialing 877-270-2148 or 412-902-6510.

Live Webcast Information: Interested parties can access the conference call via a live Internet webcast, which is available in the Investor Relations section of the Company’s website at or

Replay: A teleconference replay of the call will be available through April 6, 2021 at 877-344-7529 or 412-317-0088, confirmation #10153332. A webcast replay will be available in the Investor Relations section of the Company’s website at for 90 days.

Post View Count : 120


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us